A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma

Determining the BRAF mutation status of patients with advanced metastatic melanoma is essential in order to assess patients' eligibility for targeted BRAF inhibitor therapy. The aim of this study was to validate the utility of immunohistochemistry (IHC) to rapidly obtain the BRAF status in the...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2016-07, Vol.115 (2), p.223-227
Main Authors: Lo, Michelle Chin I, Paterson, Anna, Maraka, Jane, Clark, Richard, Goodwill, Joseph, Nobes, Jenny, Garioch, Jennifer, Moncrieff, Marc, Rytina, Ed, Igali, Laszlo
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - immunology
Audit departments
Feasibility Studies
Histopathology
Humans
Immunohistochemistry
Melanoma
Melanoma - genetics
Melanoma - pathology
Metastasis
Molecular Diagnostics
Monoclonal antibodies
Mutation
Neoplasm Metastasis
Proto-Oncogene Proteins B-raf - genetics
Skin cancer
Stains & staining
United Kingdom
Validation studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Determining the BRAF mutation status of patients with advanced metastatic melanoma is essential in order to assess patients' eligibility for targeted BRAF inhibitor therapy. The aim of this study was to validate the utility of immunohistochemistry (IHC) to rapidly obtain the BRAF status in the UK cancer centre setting. All samples sent for molecular testing for detection of the BRAF mutation over a 26-month period were prospectively tested using the VE1 monoclonal antibody IHC stain. Two-hundred and nineteen samples from 214 patients were identified. All patients were AJCC stage III/IV, except one. There was an overall 95.0% (208/219) concordance rate, with a sensitivity of 94.4% (84/89) and a specificity of 95.4% (124/130) when using genomic assays as the gold standard. Discordance resulted from the inability of the molecular technique to detect the V600E2 mutation and an inability of the IHC staining technique to detect non-V600E mutations. Molecular testing on smaller tumour deposits was also unreliable. IHC staining has good sensitivity and excellent specificity for BRAF V600E mutations. BRAF IHC can be incorporated into a BRAF mutation testing algorithm for UK cancer centres to as a feasible first-line assay and identify a subset of cases that require subsequent genomic testing. It has the additional major advantages of reduced cost and rapid turnaround time.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2016.106